Work

RAD51C-Deficient Cancer Cells Are Highly Sensitive to the PARP Inhibitor Olaparib

Year: 2013

Type: article

Source: Molecular Cancer Therapeutics

DOI: 10.1158/1535-7163.mct-12-0950

Authors: Ahrum Min, Seock-Ah Im, Young-Kwang Yoon, Sang-Hyun Song, Hyun-Jin Nam, Hyung-Seok Hur, Hwang-Phill Kim, Kyung-Hun Lee, Sae-Won Han, Do-Youn Oh, Tae-You Kim, Mark J. O'Connor, Woo-Ho Kim, Yung-Jue Bang

Institutions: AstraZeneca (United Kingdom), Seoul National University

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Université Laval

OpenAlex ID: W2151876400

FWCI: 6.038

Cites: 37

Cited by: 143

Related to: 10